Skip to content

Study · Randomized controlled trial · n = 161 · 2004

6 results

The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.

Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L and 5 more

Show all authors

Schwab T, Farrington J, Taylor AM, Ng J, Fuh V

Journal of the American Geriatrics Society1 Apr 2004Cited by 58 (Europe PMC)

PMID15066065 (opens in a new tab)DOI10.1111/j.1532-5415.2004.52156.x (opens in a new tab)PepBankPUB-15066065
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, MK-0677 increased serum IGF-I by 84%, compared with 17% on placebo.

    In plain wordsIn older hip-fracture patients, MK-0677 increased IGF-I more than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseSerum IGF-I
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    Serum IGF-I increase
    84%
    MK-0677
    Serum IGF-I increase
    17%
    placebo
    95% confidence interval for serum IGF-I increase
    63 to 107%
    MK-0677
    95% confidence interval for serum IGF-I increase
    8 to 28%
    placebo

    Source sentences

    Summary
    MK-0677 treatment increased serum IGF-I levels by 84% (95% confidence interval (CI)=63-107), compared with an increase of 17% (95% CI=8-28) on placebo.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, functional performance improvement did not differ significantly between MK-0677 and placebo.

    In plain wordsIn older hip-fracture patients, functional performance improvement did not differ significantly between MK-0677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeFunctional performance measures
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between MK-0677 and placebo in improvement in functional performance measures or in the overall SIP-NH score.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, overall SIP-NH improvement did not differ significantly between MK-0677 and placebo.

    In plain wordsIn older hip-fracture patients, overall SIP-NH improvement did not differ significantly between MK-0677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeOverall SIP-NH score
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between MK-0677 and placebo in improvement in functional performance measures or in the overall SIP-NH score.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, greater improvement with MK-0677 in three of four lower-extremity measures versus placebo was not significant.

    In plain wordsIn older hip-fracture patients, greater lower-extremity improvement with MK-0677 than placebo was not statistically significant.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeLower extremity functional performance
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    Lower extremity functional performance measures with greater improvement
    3 measures
    MK-0677 relative to placebo; differences were not statistically significant
    Lower extremity functional performance measures assessed
    4 measures
    MK-0677 relative to placebo

    Source sentences

    Summary
    Although MK-0677 patients showed greater improvement relative to placebo in three of four lower extremity functional performance measures, in the physical domain of the SIP, and in the ability to live independently, these differences were not statistically significant.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, greater SIP physical-domain improvement with MK-0677 than placebo was not statistically significant.

    In plain wordsIn older hip-fracture patients, greater physical-domain improvement with MK-0677 than placebo was not statistically significant.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeSIP physical domain
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Although MK-0677 patients showed greater improvement relative to placebo in three of four lower extremity functional performance measures, in the physical domain of the SIP, and in the ability to live independently, these differences were not statistically significant.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In older hip-fracture patients, greater improvement in independent living with MK-0677 than placebo was not statistically significant.

    In plain wordsIn older hip-fracture patients, greater independent-living improvement with MK-0677 than placebo was not statistically significant.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeIndependent living
    Study

    n = 161

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Although MK-0677 patients showed greater improvement relative to placebo in three of four lower extremity functional performance measures, in the physical domain of the SIP, and in the ability to live independently, these differences were not statistically significant.
    3 context sentences
    Summary · context
    Placebo-controlled, randomized, double-blind trial.
    Summary · context
    Entry criteria included consenting hip-fracture patients who were aged 65 and older and who were ambulatory before their fracture, medically stable postoperatively, and mentally competent.
    Summary · context
    Random assignment to 6 months of daily treatment with MK-0677 or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.